ライフサイエンスコーパス: acetazolamide

1 lpha-CA deletion mutant and the CA inhibitor acetazolamide.

2 symmetric blood flow and normal response to acetazolamide.

3 edly low blood flow and abnormal response to acetazolamide.

4 c paralysis and the patient's worsening from acetazolamide.

5 ding pilocarpine, epinephrine compounds, and acetazolamide.

6 ertigo and ataxia that are not responsive to acetazolamide.

7 (n = 7) was injected intravenously with 1 g acetazolamide.

8 to 12.56; P < .001) were also observed with acetazolamide.

9 f interaction between carbonic anhydrase and acetazolamide.

10 s of dilation despite pretreatment with oral acetazolamide.

11 relate to the reported beneficial effects of acetazolamide.

12 carbonic anhydrase (CA) inhibitors, such as acetazolamide.

13 ree-fold by the carbonic anhydrase inhibitor acetazolamide.

14 The mean improvement in PMD was greater with acetazolamide (1.43 dB, from -3.53 dB at baseline to -2.

15 Mean improvements in papilledema grade (acetazolamide: -1.31, from 2.76 to 1.45; placebo: -0.61,

16 In addition, under the conditions used here, acetazolamide (100 microM) did not have a significant ef

17 lication of the carbonic anhydrase inhibitor acetazolamide (100 microM) in the presence of CO2/HCO3-

18 occurred in 59% of rats receiving high-dose acetazolamide (200 mg/kg).

19 rats (n = 100) were randomized to either IP acetazolamide, 200 mg/kg (high-dose), or IP saline twice

20 Acetazolamide (222 g/mol) binding to carbonic anhydrase

21 The acetazolamide (3.6 mum) and placebo (2.1 mum) groups sho

22 but was reversed by reacidifying the blood (acetazolamide; 3% FiCO2).

23 Low-dose acetazolamide (50 mg/kg) produced a pH (7.22 +/- 0.07) t

24 Acetazolamide (50 microM) doubled the size of the dendri

25 of acidosis induced by intraperitoneal (IP) acetazolamide (50 or 200 mg/kg) or saline.

26 n rats (n = 75) were randomized to either IP acetazolamide, 50 mg/kg (low-dose), or IP saline twice d

27 Acetazolamide (500 mg twice daily) was administered for

28 Dorzolamide and acetazolamide (500 microM) did not show additive inhibit

29 Acetazolamide (500-1000 mg, twice daily) vs placebo admi

30 mide also experienced a reduction in weight (acetazolamide: -7.50 kg, from 107.72 kg to 100.22 kg; pl

31 At altitude, patients either took acetazolamide (750 mg/d) or placebo in addition to autoC

32 asured by the National Eye Institute VFQ-25 (acetazolamide: 8.33, from 82.97 to 91.30; placebo: 1.98,

33 and its 10-item neuro-ophthalmic supplement (acetazolamide: 9.82, from 75.45 to 85.27; placebo: 1.59,

34 f motor coordination that was ameliorated by acetazolamide, a carbonic anhydrase inhibitor that minim

35 Acetazolamide, a membrane-permeable CA inhibitor, was us

36 in this study, consisting of a derivative of acetazolamide, a spacer, and a peptidic (99m)Tc chelator

37 drase isoforms I, II, IX, XII, and XIV using acetazolamide (AAZ) as reference compound.

38 Infusion of acetazolamide abolished the positive PD in the later seg

39 in the presence and absence of HCO(3)(-) and acetazolamide (ACTZ) using tissue treated with siRNA spe

40 substance associated with doping in sports: acetazolamide (ACTZ).

41 h and without niflumic acid (MCT inhibitor), acetazolamide (ACTZ, a CA inhibitor), 5-(N-Ethyl-N-isopr

42 determine whether the beneficial effects of acetazolamide (ACZ) in improving vision at 6 months cont

43 Acetazolamide (ACZ) is used to prevent acute mountain si

44 al trial, study eyes of subjects assigned to acetazolamide (ACZ, n = 44) or placebo (PLB, n = 43) had

45 obstructive sleep apnoea (OSA).However, how acetazolamide affects the key traits causing OSA remains

46 Participants assigned to acetazolamide also experienced a reduction in weight (ac

47 reasing distal volume delivery elicited with acetazolamide also led to increases in renal interstitia

48 ha-CA knockout mutant and in the presence of acetazolamide, although UreI and urease remained fully f

49 ated HCO(3)(-) secretion was not affected by acetazolamide, an inhibitor of carbonic anhydrase.

50 he high-power LFOs are decreased markedly by acetazolamide and 4-aminopyridine, the primary treatment

51 Acetazolamide and autoCPAP resulted in better control of

52 derately elevated altitude, a combination of acetazolamide and autoCPAP therapy, compared with autoCP

53 Acetazolamide and autoCPAP treatment was associated with

54 Both acetazolamide and DIDS reduced chloride effluxes.

55 Treatment of algae with the CA inhibitors acetazolamide and ethoxyzolamide decreased photosyntheti

56 Acetazolamide and glucose infusion resulted in a negativ

57 /- 0.4 ms, S.E., n = 11 mice) and blocked by acetazolamide and increasing external pH (to decrease CO

58 Inhibition of total CA activity with acetazolamide and inhibition of extracellular-facing mem

59 avoided, and proximally acting agents (e.g., acetazolamide and loop diuretic agents) are preferred.

60 the right eye even under treatment with oral acetazolamide and maximal tolerated doses of topical ant

61 free conditions, DIDS, and the CA inhibitors acetazolamide and methazolamide but not by the Na-H exch

62 ated with cGMP production and is enhanced by acetazolamide and raloxifene.

63 ngestion of the carbonic anhydrase inhibitor acetazolamide and the ion exchange inhibitor DIDS (4,4'-

64 hdrawal, to the carbonic anhydrase inhibitor acetazolamide and to H2DIDS inhibition.

65 In IIH, acetazolamide and weight loss effectively improve RNFL t

66 Finally, the blockade of water entry by acetazolamide attenuated ballooning in vitro and markedl

67 contributes to lithium-NDI development, and acetazolamide attenuates lithium-NDI development in mice

68 arbonic buffer was increased again by adding acetazolamide (ATZ), a membrane permeant carbonic anhydr

69 wed by the carbonic anhydrase (CA) inhibitor acetazolamide (ATZ).

70 luorescent derivative of the CA IX inhibitor acetazolamide (AZ).

71 se IX (CAIX) overexpression and inhibited by acetazolamide (AZA) administration.

72 The clinically used acetazolamide (AZM) is a sulfonamide that binds with hig

73 ith AE2, these latter two being sensitive to acetazolamide because of their association with the cyto

74 failure, administration of a single dose of acetazolamide before sleep improves central sleep apnea

75 x with five CA sulfonamide-based inhibitors (acetazolamide, benzolamide, chlorzolamide, ethoxzolamide

76 Variability in the quality of the acetazolamide binding responses was likely a product of

77 Although we detected acetazolamide binding to immobilized CA II and specific

78 Our findings suggest that acetazolamide can improve OSA, probably due to reduction

79 sessment of cerebrovascular reserve by using acetazolamide challenge in patients with intracranial va

80 tric blood flow and abnormal response to the acetazolamide challenge test may require a revasculariza

81 mography (CT) in the resting state and after acetazolamide challenge.

82 on and apoptosis in PC12 cells; and (3) that acetazolamide, chlorthalidone, and the neurosteroid, all

83 invasive mechanical ventilation, the use of acetazolamide, compared with placebo, did not result in

84 Acetazolamide completely blocked the increase in Cl(-)/H

85 CA XIV at 2.8 A resolution and of an enzyme-acetazolamide complex at 2.9 A resolution.

86 "130's segment." The structure of the CA XII-acetazolamide complex is also reported at 1.50-A resolut

87 Additionally, the structure of the acetazolamide complex is essentially identical to that o

88 groups onto the par excellence CA inhibitor acetazolamide, compounds that may interact with the dist

89 The acetazolamide conjugate described in this study could be

90 The (99m)Tc-labeled acetazolamide conjugate exhibits high tumor uptake and f

91 erties of said ligand and understand whether acetazolamide conjugates merit further development as dr

92 The effects of acetazolamide could be mimicked by either amiloride or b

93 The effects of acetazolamide could be mimicked by removal of HCO3-/CO2

94 y questions remain regarding the efficacy of acetazolamide, CSF shunting procedures and cerebral tran

95 We have previously described a novel acetazolamide derivative, a carbonic anhydrase ligand wi

96 Acetazolamide did not affect the cotransport stoichiomet

97 ups 72 hrs after administration of the first acetazolamide dose (31.8 +/- 4.9-25.3 +/- 3.8 mEq/L, p <

98 atients with symmetric blood flow and normal acetazolamide-enhanced challenge test results will do we

99 nic anhydrase inhibitor (CAI); however, CAIs acetazolamide, ethoxyzolamide, dichlorphenamide, chlorth

100 r inhibitors, among which are methazolamide, acetazolamide, ethoxzolamide, dorzolamide, brinzolamide,

101 For the acetazolamide group (n = 187), compared with the placebo

102 At 6 months, the acetazolamide group had greater reduction than the place

103 < .001) decreased significantly more in the acetazolamide group.

104 potency series of thiazide diuretic action (acetazolamide > chlorothiazide > metolazone) differed si

105 An inhibitor of CAs, acetazolamide has been reported to inhibit invasion.

106 The carbonic anhydrase inhibitor acetazolamide has been used as a treatment for hypokalae

107 Acetazolamide has been used for decades as a respiratory

108 With the addition of acetazolamide, however, acid-base balance as well as ENa

109 Acetazolamide improved subjective perception of overall

110 , double-masked, placebo-controlled study of acetazolamide in 165 participants with IIH and mild visu

111 tested the effect of the CA-specific blocker acetazolamide in lithium-NDI.

112 Trial (IIHTT) reported beneficial effects of acetazolamide in patients with mild visual loss.

113 scans show more extensive hypoperfusion than acetazolamide in the two cases.

114 Acidosis induced by high-dose acetazolamide, independent of hyperoxemia or hypoxemia,

115 Studies in mice treated with acetazolamide indicated that increased bicarbonate and f

116 study, the following hypothesis was tested: acetazolamide-induced acidosis is associated with preret

117 It can be assessed by measuring the acetazolamide-induced change in regional cerebral blood

118 Acetazolamide induces a metabolic acidosis via an altern

119 Acetazolamide inhibited the carbonic anhydrase activity

120 Acetazolamide inhibited the short-circuit current throug

121 increased more after dipyridamole than after acetazolamide injection in two patients.

122 Acetazolamide is a mild diuretic and a respiratory stimu

123 Acetazolamide is commonly used to treat idiopathic intra

124 in complex with a nonspecific CA inhibitor, acetazolamide, is available in Protein Data Bank.

125 species, reducing aqueous humor inflow with acetazolamide lowered IOP and administering water intrap

126 There is some evidence to suggest that acetazolamide may improve obstructive sleep apnoea (OSA)

127 al of HCO(3)(-)/CO(2) was inhibited by DIDS, acetazolamide, methazolamide, and low-chloride buffer.

128 Furosemide but not acetazolamide (n = 6 each) increased medullary oxygenati

129 0.06, P < 0.001); however, neither low-dose acetazolamide nor saline induced preretinal neovasculari

130 examine the prolonged duration of action of acetazolamide observed in this study as well as the effe

131 erved in this study as well as the effect of acetazolamide on clinical end points, such as duration o

132 We aimed to investigate the effect of acetazolamide on the traits contributing to OSA and its

133 zed to receive intravenous administration of acetazolamide, one dose of 500 mg or 250 mg every 6 hrs

134 dependent chloride/bicarbonate exchange with acetazolamide or chlorthalidone.

135 lated by 7,8-benzoquinoline and inhibited by acetazolamide or HCO3-/CO2 removal can be said to repres

136 This effect is not blocked by acetazolamide or MK-801, indicating that permeability of

137 structures of CrCAH3 in complex with either acetazolamide or phosphate ions were determined at 2.6-

138 ion for more 24 hours were randomized to the acetazolamide or placebo group and 380 were included in

139 d to a double-blind cross-over protocol with acetazolamide or placebo, taken 1 h before bedtime for s

140 CO(2) did not change after administration of acetazolamide or progesterone.

141 Treatment of lithium-NDI mice with acetazolamide or thiazide/amiloride induced similar anti

142 y dilation was enhanced by administration of acetazolamide (oral or intra-arterial) and oral raloxife

143 s intermediate between high-dose (200 mg/kg) acetazolamide (P < 0.001) and saline controls (7.42 +/-

144 o-plus-diet or maximally tolerated dosage of acetazolamide-plus-diet.

145 High-dose acetazolamide produced a severe acidosis (pH 7.13 +/- 0.

146 pupillary dilation with tropicamide and oral acetazolamide prophylaxis.

147 and analyzed an identical dilution series of acetazolamide (ranging from 4.1 to 1000 nM).

148 In the intact eye, DIDS and acetazolamide reduced AH secretion by 25% and 44%, respe

149 d mice with the carbonic anhydrase inhibitor acetazolamide reduced lung inflammatory pathology withou

150 Preblocking with acetazolamide reduced more than 80% uptake of (18)F-AmBF

151 In collecting duct (mpkCCD) cells, acetazolamide reduced the cellular lithium content and a

152 Acetazolamide reduced the median [interquartile range] L

153 Preventive use of acetazolamide reduced the relative risk of SHAI by 44%.

154 s of complexes of HpalphaCA with a family of acetazolamide-related sulfonamides have been determined.

155 We conclude that a single 500-mg dose of acetazolamide reverses nonchloride responsive metabolic

156 Diffusion coefficients are obtained for acetazolamide, riboflavin, sodium fluorescein, and theop

157 theless, purified CanB (a dimeric, anion and acetazolamide sensitive, zinc-containing type II beta-cl

158 An acetazolamide stress SPECT image was also obtained in tw

159 In comparing placebo with acetazolamide, the hourly number of episodes of central

160 In the mutant or in the presence of acetazolamide, there was an approximately 3 log10 decrea

161 nderlie the reduced urinary PGE2 levels with acetazolamide, thereby contributing to the attenuation o

162 Drugs that decrease inflow (acetazolamide, timolol) or increase outflow facility (pi

163 urple (MFCP) was tested in mice treated with acetazolamide to cause urinary alkalinization, and Ceren

164 duct, or gave aldosterone and NaHCO(3) plus acetazolamide to increase luminal HCO(3)(-) concentratio

165 In vivo, the bladders of acetazolamide-treated mice exhibited a wavelength-depend

166 s previously observed in patients but not in acetazolamide-treated mice in this study.

167 -1)) 0.37 +/- 0.04 (control), 0.16 +/- 0.03 (acetazolamide-treated), and 1.14 +/- 0.15 (forskolin-tre

168 Furthermore, acetazolamide treatment reduced inulin clearance and cor

169 diet plus the maximally tolerated dosage of acetazolamide (up to 4 g/d) or matching placebo for 6 mo

170 Analysis was stratified according to acetazolamide use.

171 stent with this hypothesis, the CA inhibitor acetazolamide was found to be a strong inhibitor of gluc

172 A dose of oral acetazolamide was given before the patient left the clin

173 hese results show that the antidiuresis with acetazolamide was partially caused by a tubular-glomerul

174 In the BNP-driven group, furosemide and acetazolamide were given more often and in higher doses

175 lated by 7,8-benzoquinoline was sensitive to acetazolamide, which caused up to 50 % inhibition of the

176 ts with IIH and mild visual loss, the use of acetazolamide with a low-sodium weight-reduction diet co

177 ibited by the sulfonamides ethoxzolamide and acetazolamide, yielding the lowest Ki values measured by